WARRENDALE, Pa., November 16, 2010 – MEDRAD will offer RSNA* attendees hands-on demonstrations of personalized-protocol software that individualizes CT Pulmonary Angiography (CTPA) contrast dosing, and has proven to increase the percentage of diagnostic-quality studies to rule out Pulmonary Embolism (PE) when compared to the institution’s standard protocol1** -- potentially obviating the need to rescan the patient.2 Diagnosis with a high degree of certainty is critical to the safety of patients with suspected PE, yet can be inhibited by imaging complexities associated with these studies. PE, a blockage of the pulmonary artery or one of its branches due to a blood clot or other thrombus, results in as many as 50,000 deaths a year,1 most of which occur in the first few hours.
MEDRAD’s P3T® PA (Pulmonary Angiography) software enables increased diagnostic quality studies by fitting into the established CTPA workflow and making consistent administration of personalized dosing practical. The only contrast-dosing solution of its kind, the clinically validated P3T algorithm tailors each patient’s contrast protocol based on technologists’ touch-screen responses to unique clinical concerns, study requirements, and the scanning equipment used.
“Achieving a diagnostic CT image for Pulmonary Embolism, without limitations, helps the hospital and emergency department in a number of important ways -- with efficiency, patient care, and cost savings,” says Joan Lacomis M.D., Clinical Professor Radiology, The University of Pittsburgh Medical Center.
source: Medrad
Subscribe to:
Post Comments (Atom)
1 comment:
The doctors diagnose the cancer and determine what kind it is by looking at a sample of the tumor under a microscope. This alone does not determine what treatment you can have. Before treatment, your doctors must determine if or how much the lung cancer has spread. This is called staging the cancer.
http://computedtomographyscan.blogspot.com/
Post a Comment